Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's disease (AD), but its role in the brain was unknown until now.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

A simpler method of analyzing blood samples for Alzheimer's disease has been tested in a large multicenter study led by Lund ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its ...

Quest Diagnostics (DGX) launched a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

A new study is part of a growing body of evidence that vaccination against shingles—and potentially other infections—can be ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

H.C. Wainwright argues that Voyager’s presentations at the Alzheimer’s & Parkinson’s Disease meeting April 1-5 “further strengthen the ...